Become a Member

“#1 Micro-Cap Stock for February” teased — what’s up with this “1,000% gains starting February 22” pitch from Behind the Markets?

What's being teased in the Breakthrough Wealth pitch from Dylan Jovine?

By Travis Johnson, Stock Gumshoe, January 26, 2021

Everyone seems to love a “micro cap” these days, so the latest teaser pitch from Dylan Jovine over at Behind the Markets for his “upgrade” newsletter caught my eye — it’s called Breakthrough Wealth ($997/yr, 30-day refund policy), and he’s pitching a service that he says will be shooting for 1,000% gains in small companies.

Here’s part of the spiel…

“My name is Dylan Jovine.

“while making nearly 490% on your money just ONCE would be a huge victory…

“Target 1,000% can potentially deliver those types of life-changing returns…

“Month after month…

“All year long.

“As long as you have five minutes a day to spare…

“And can press a couple of buttons on your phone or computer…”

Which sounds fun, of course — though as we all should know by now, when you shoot for 1,000% gains in any kind of short time frame (less than 5-10 years), you’re going to be taking big chances. Risk and reward are always tied together, at least when you’re dealing with a whole portfolio of stocks and looking at averages.

And to entice new subscribers, he dangles this “#1 pick” that he says je just identified…

“Because just hours ago, a tiny micro-cap company…

“Whose stock is trading for just $6 a share right now…

“Lit up the screens at Target 1,000% HQ.

“And our modeling algorithms indicate that starting on February 22, 2021, the value of this small company could skyrocket by up 1,000% or more…

“And potentially turn every $5,000 invested into $50,000.

“This is the best profit opportunity Target 1,000% has ever detected.”

So that’s what we’re curious about — what is this little fella?

We get some more spiel… reinforced by the notion that these little micro-cap stocks are under-followed because the big institutional investors really can’t get involved…

“The truth is that most Wall Street firms are banned from buying micro-cap stocks.

“They’re just too big. A $100 billion mutual fund can’t realistically buy shares in a company with a $100 million micro-cap.

“That means we’re not competing with Wall Street giants that have armies of researchers working for them.

Are you getting our free Daily Update
"reveal" emails? If not,
just click here...


“That means there’s less competition. And that gives us a powerful advantage.”

And he says that the stocks he’s picking these days for huge returns are a lot trickier than the ones he liked the last time the market created some real “crash” values…

“… most of the money I’ve made investing has been when something bad happens to a company and the stock plummets.

“Just like during the 2009 Market Crash. It wasn’t hard to buy American Express at $13 or Starbucks at $18. Those were no-brainers.

“But now we have a consistent way to spot these in the market even when the market isn’t crashing.”

I don’t know about that — don’t wash the sentiment most of us had following the 2009 crisis memory away that easily — I was buying stocks in 2009 and it was often HARD. Everyone was just beginning to recover from the idea that the world almost came to an end, and while I did end up with some big winners back then I also specifically remember looking at some stocks that were no-brainers in retrospect, like 3M (MMM) in the $30s and Starbucks (SBUX) around $15-20, and passing because I was feeling so cautious. It’s not easy — and, of course, the pundits didn’t make it any easier by screaming about stimulus and Wall Street failing “Main Street” and the fact that we had a new “socialist” in the White House who was going to burn it all down (sound familiar?)

But anyway, before we get to the clues let’s look quickly at the criteria Jovine says he’ll be using for these stock picks…

“Our goal is to make as much money as possible with as little risk as possible.

“And mark my words – it’s the second part of that statement that made this challenging.

“So, I painstakingly went through 50 years of market data.

“I was obsessed with answering one question….

“What do stocks that go up 1,000% in a year have in common?”

That’s the kind of navel-gazing we all do, of course, and there’s no mathematical answer — if there were, it would disappear in a matter of months as the computers absorb it into their trading algorithms. But sure, there are common themes that come up with the big long-term winners… here’s what they pitch as the “key ingredients” they’re looking for:

“Ingredient #1: A Company Has to Have a Unique Advantage….

“Put simply, we have to avoid copycats….

“This could be a new drug, new technology, a new system for doing something, a new medical device.

“Or it could be the best piece of property in an exclusive location.”

OK, so some sort of “special sauce” uniqueness for the company. Can’t argue with that. Next?

“Ingredient #2: A Large Gap Between the Value of a Company and What the Common Stock is Selling for

“As soon as I see a company has a unique advantage, I need to make sure there’s deep value in the shares….

“You can have the greatest company in the world, but if the stock is selling for more than the company is worth, its not worth buying. “

OK, so that’s a “duh” factor — of course we want to pay “less than it’s worth.” Sadly, “what it’s worth” is subjective… and there are few obvious “values” around these days. That must be a “can I justify this price for the business” question, not a particular book value or PE ratio or whatever else.

Next…

“Key Ingredient #3: First-time institutional buying.

“You can have a great company, but if nobody knows about them the stock isn’t going to move.

“I’ve seen some great companies whose stocks barely move because nobody knows they exist….

“For a Stock to Rise 1,000% Institutional Ownership has to Rise 1,000% too.”

OK, so it has to be so small that institutions can’t buy it… but institutions also have to be buying it.

And one final criteria…

“Key Ingredient #4: The Stock must trade for less than $10 a share….

“The research proves that stocks priced between $1 and $25 are most likely to move 1,000%.

“Now remember guys, not every investment is going to pan out.

“Our goal is to make high-probability investments.”

That last part is a key consideration for any investor, of course — we often get hung up imagining the possible gains or possible losses and don’t take the time to make more specific guesstimates about how probable they may be. You can gamble, but you should think about the money at risk and be honest with yourself about the odds when you do.

So finally, what’s this stock? More from the ad:

“I’m really pumped up about this. It’s the most excited I’ve been since I recommended Intelsat in our first issue of Behind the Markets.

“But unlike Intelsat which soared 500% in 5 months, I think people are going to be talking about this one for years and years…

“It has all the common denominators of success we talked about earlier (1) a unique advantage; (2) deep value, (3) first-time institutional buying and (4) a share price under $10.”

And then we get a little diagram of a capsule with a double helix inside it…

“What you’re looking at right now is a picture of this company’s breakthrough technology — ‘Cancer Blocker’…

Ah, no it isn’t — that’s a stock photo that’s used to illustrate “genetic engineering” articles. Not sure which agency sells it, if I knew I’d buy a copy as well so I could share it with you, but, well, here’s a similar image I licensed from Getty, just to give you the general idea.

So… what is this little company? Here are our clues:

“I call it ‘Cancer Blocker’ Because it Attacks Cancer at a DNA Level by Blocking the Cells from Reproducing.

“This causes tumors to shrink and die.

“It was first discovered by some of scientists in San Diego working in collaboration with scientists from Oxford, England.”

OK… so what does this “cancer blocker” do? He shows a little image that seems to indicate that it stops cancer cells from repairing their DNA after chemotherapy by sending an “SOS message” … which is done through something he calls “PARP1 Upregulation” — which I know nothing about, but we’ll use that as a clue as well.

Other hints?

“The FDA approved ‘Cancer Blocker’ after it doubled patient survival times during clinical trials….

“… right now the drug is being given to people already on chemotherapy.

“That’s only 20% of patients.

“What if you were able to move the treatment to the front lines.

“Give the drug what we call front-line status.”

So that means he sees this drug as possible going from a fairly small market to a large market — getting used not just as a last resort, but maybe as a first-line treatment someday. Which can certainly be a big deal if it happens, financially.

And he implies that this drug might work in other cancers, too…

“Could it work with breast cancer? Lung cancer? Pancreatic cancer?

“The short answer is yes….

“… some cancers are more sensitive to this kind of treatment than others.

“Specifically, ‘Cancer Blocker’ is most effective with low-oxygen (i.e fast growing) cancers.

“Cancers like –

“Ovarian Cancer which strikes 21,000 people a year

Prostate Cancer which strikes 174,000 people a year

“Bladder Cancer which strikes 80,000 people a year

“Brain Cancer which strikes 21,500 people a year

“By treating all these different types of cancer, ‘Cancer Blocker’ can save the lives of 330,000 people each year.

“Because of the size of the market, we believe this stock should be selling for $100 a share.

“But the stock is only selling at $6 a share.”

So…. hoodat?

First, we get the hard sell…

“Anyone who joins my research service Breakthrough Wealth, and invests $10,000 following my recommendations, will have the chance to earn a profit of $100,000… in the next year.

“If it doesn’t, then I’ll work an entire second year for them, free of charge.”

Ah, the good ol’ “If it’s not as good as I promise, I’ll give you twice as much of it” guarantee. Does that cheeseburger taste a little rancid? Don’t worry, I’ll give you another one for free! The beauty of the newsletter business is that it is almost 100% scalable at no marginal cost — even more so now that most newsletters don’t send physical copies. Sending your newsletter to 101 people costs the same amount as sending it to 1,001 people… the only scalable cost is the cost of advertising, convincing each new subscriber to sign up, and once you’ve signed up that’s a sunk cost against the price you paid.

But, to be fair, the order form does also say that there’s a 30-day guarantee, so you can get your money back if the service turns out to be something entirely different than you expected. I don’t know exactly how they fulfill that promise, but I do think every service should offer something along those lines, particularly when they’re roping people in by dangling financial porn in front of your eyes (Three 1,000% gains a month! Make $100,000 in a few months!), so I should cheer Dylan for doing that — a lot of the big publishers offer no money-back guarantee at all for their higher-priced newsletters. Push hard on the marketing, sure, but give people a chance to back out if they just got over-excited by the hype, and what’s behind the curtain was not what they expected.

So anyway, back to the point… what’s our stock? Thinkolator sez this is little Clovis Oncology (CLVS)

Clovis is not a microcap, but it is pretty small — I’d call it a regular ol’ “Small Cap,” with a market cap a few days ago of about $700 million at a $6.50 share price (it’s up to $8.20 now, thanks to some market enthusiasm and, perhaps, some additional “short squeeze” trading like we’ve seen in so many stocks recently — and perhaps thanks in part to Jovine’s attentions). Clovis is a bit of a grizzled survivor in the small cap biotech space at this point — this was a $4 billion company when it was on the verge of an expected approval for their lung cancer drug, rocelitinib, about five years ago… and the FDA rejected that and it was abandoned, then it soared again into 2017 and 2018, mostly on hopes for this PARP inhibitor that is the focus of the teaser pitch, rucaparib (brand name Rubraca), and dreams that Clovis would be acquired (like Tesaro, which makes the competing drug Zejula and was bought for $5 billion by GlaxoSmithKline around that time).

There is a reasonable amount of institutional ownership of Clovis shares, as you’d expect for a biotech that’s been around for a while, but it has generally been rising a bit — the biggest shareholders are the index fund managers, of course, but there are some active funds that have been buying a little more, too, including a few health care-focused managers like Palo Alto Investors and Armistice Capital. I don’t know enough about them to be excited or dissuaded by their presence.

Clovis does keep getting new indications approved for Rubraca, it appears (three now, I think), and studying it in late-stage studies in new cancers, so there is some realistic possibility that the market could become meaningfully larger, either as a solo drug or in combination with some other cancer drugs… but it has not yet become a really meaningful revenue producer.

There has been some concern over the years about Rubraca losing patent protection, since this drug took a long time to get developed and is starting off fairly small on the sales front in its first years — I guess that’s because the first rucaparib patents start to expire in a couple years, but they also do say that they’ve extended those patents with new claims on higher doses and forms and methods, and that they believe they have protection until 2035. Which would be particularly helpful if they get into some higher-volume indications for broader use.

I have no idea what the competitive landscape is, but there is competition (and yes, the technology does have roots in Oxford, as teased, there’s an interesting short piece about the basic technology of PARP inhibitors here that goes into that, if you’re curious). How Rubraca compares with other PARP inhibitors or other treatments for ovarian or prostate cancer is a closed book for me, I’m certainly not going to become an oncologist overnight… but, well, it does seem that it at least works well enough to get sales growing. They launched some new indications last year, and sales have stayed at a decent level despite the general slowdown of non-COVID work in hospitals, even starting to grow a tiny bit in the fourth quarter.

And yes, to further match up with those clues, the expectation is that they will report their next quarterly earnings on February 23 — and they have already preannounced their revenue estimates. Earnings dates aren’t generally hugely important for biotech companies, they aren’t nearly as important as clinical data releases can be, but if they say anything meaningfully different than that about the last quarter… or issue exciting guidance for 2021 because of promising sales to start the year… well, that could impact the shares in the near term. Not hugely likely, I would guess, biotechs tend to try to get their most exciting news out at the JP Morgan Healthcare Conference, when everyone is listening.

So that little bit of growth in the fourth quarter, combined with some optimism about their next product candidate when they presented at that conference earlier this month, seems to have helped juice the shares a bit, too. Here’s a little excerpt from an Informa summary from their presentation:

“Clovis Oncology CEO, Patrick Mahaffy, reiterated Clovis’ strong position in second line maintenance in ovarian cancer space with strong market uptake despite challenges posed by COVID-19. Mahaffy then noted the company transition from its main growth driver, Rubraca, to a true commercial stage biotech with multiple indications and expanded pipeline. The first noteworthy highlight was the US approval of Rubraca in May 2020 for mCRPC, the first approval in its class in prostate setting. With a 55% PSA response, Clovis expected a gradual uptake in the prostate cancer landscape despite virtual launches from COVID-19 due to many physicians’ consideration of PSA response being a predictor of a tumor’s behavior. Additional ongoing studies of Rubraca were also discussed, with a prominent focus on upcoming monotherapy readout from Phase III ATHENA study in the second half of 2021.

“However, the star of the presentation was the enthusiastic showcase of a new candidate, FAP2286. Mahaffy introduced FAP-2286 as Clovis’ foray into a new opportunity in radionuclide therapy, following the success of Lutathera…. Mahaffy reported that Clovis is shying away from M&A deals to focusing on its existing asset, FAP-2286, making late 2021 – early 2022 an important inflection point for Clovis Oncology.”

So with that laid out as a possibility, maybe adding a second attention-getting drug to a portfolio that is generating revenue and growing (if not nearly enough revenue to make a profit just yet), and with enough cash on hand to make some good progress on that new drug… this seems like a somewhat interesting speculation on an almost “back from the dead” biotech (OK, not dead… but at least sleeping). I don’t typically invest in small single-product drug stocks, or much in biotech at all, but I’ll put a little flier on the long-term options (January) for this one, just to see if they can catch some lightning with early attention on this new drug (or, perhaps, some surprisingly strong growth for Rubraca). I’ll mostly ignore that for a while and it’s a tiny speculation, but it will show up in the Real Money Portfolio for the Irregulars on Friday.

If you think I’m crazy, or are enthused about Clovis Oncology yourself… or, for that matter, if you have a different favorite microcap that you think has a chance for 1,000% gains, well, feel free to share your thoughts with a comment below. Thanks for reading!

Disclosure: I own shares of 3M and now call options on Clovis Oncology. Since this is a small and illiquid name, I’ll extend my trading embargo on Clovis for ten days from the date of publication.

Irregulars Quick Take

Paid members get a quick summary of the stocks teased and our thoughts here. Join as a Stock Gumshoe Irregular today (already a member? Log in)
guest

12345

This site uses Akismet to reduce spam. Learn how your comment data is processed.

57 Comments
Inline Feedbacks
View all comments
hedy1234
hedy1234
January 26, 2021 6:04 pm

So you bought January 2022 $17 options? the summary says Jan 21.

Add a Topic
570
👍 1691
👍 21718
ddeids
Irregular
ddeids
January 26, 2021 6:40 pm

Hi Travis, I am new to options, do you have any suggestions or pointers on how to trade options ? Thanks

Add a Topic
570
👍 12
cabaoke
Member
cabaoke
January 26, 2021 7:26 pm
Reply to  ddeids

Yeah me too. I even I even got trading options for dummies but it really felt like I got part 2. I’m not stupid (clearly not as intellectually gifted as you) but I am a foundational thinker. Any kind of “introduction” to options would be awesome.

Add a Topic
570
👍 363
rajk78
rajk78
January 26, 2021 10:18 pm
Reply to  cabaoke

Not sure if this will be helpful. If you have tdameritrade brokerage account, they have some good tutorial on options trading. Here is another video on youtube
https://www.youtube.com/watch?v=4HMm6mBvGKE&ab_channel=SkyViewTrading

Add a Topic
570
👍 27
timcoahran
Irregular
January 27, 2021 1:06 am
Reply to  cabaoke

Many of the brokers have an [EDUCATION] area of their websites. Some of those have good introductory stuff. (E-Trade is the one I’m familiar with.)

Add a Topic
#options
👍 461
tanglewood
January 27, 2021 11:36 pm
Reply to  timcoahran

Let’s walk thru Travis option trade at today’s prices. Start with your brokerage quote page for CLVS and you will see ‘chain’ or ‘Option chain’. You will see a list of several expirations, Travis selected 1/21/2022. Now within this list for call options, find $17.00 strike price. Travis paid $1.60 per share but at today’s close the current bid/ask is $2.00/$2.30 so (no surprise!) he is already making money.
Also note that you must buy options in multiple of 100 shares called contracts. So Travis paid $160.00 for each contract. So select that option and your ‘buy to open’ order will already be preloaded with the information. Just fill in the number of contracts and the type of order (limit or market).
During the course of the year, if the stock is doing well and is selling in July for $14.00, your option may be selling for $4.00 or $5.00. You could sell it then or wait for say December and maybe the stock is selling for $23.00, your option may be going for $7.00 or $8.00 (more than the difference between the strike price 17.00 and the current price 23.00) because there is still time until expiration. On expiration you can either exercise the option and own the shares at 17.00 or let it be sold.
So let’s do a ‘wallstreetbets’ and everybody jump into Clovis.

👍 644
tanglewood
January 27, 2021 11:42 pm
Reply to  tanglewood

This was meant as a reply to cabaoke

👍 644
tanglewood
January 27, 2021 9:42 pm
Reply to  cabaoke

I think it’s best to start simple. Buy basic calls or puts just to get your feet wet so to speak. I notice Travis in his Real Money Portfolio for options never has anything complex.
The other hurdle is getting your brokerage outfit to approve you for trading options. You almost have to lie about your trading experience and willingness to take extreme risk.
When you are ready to place an order, it’s best to use a limit order. Usually the bid and ask spread is wide .
I have had good luck with expirations that are at the minimum one year away and are about 20% ‘out of the money’ .You pay more premium but it gives you more time for your stock and reduces expiration anxiety.

Add a Topic
570
👍 644
jbmaverick
February 1, 2021 5:59 pm
Reply to  tanglewood

Yeah, that extra time can come in handy…plenty of times I’ve bought short expiration calls that went bust when if I’d bought the same strike price another two or three months out, I’d have made out like a bandit.

It pays to compare anyway – I’ve seen plenty of situations where buying the same strike price option another 3 or 4 months out only costs a negligible amount more. Sometimes you have to pay through the nose for that extra time, but if you take the time to look, sometimes you get a nice surprise when you see that the July call at strike price “X” is only a dime or so more than the March call – like you’ll see the March call at strike price X for 1.30 and the July call at the same strike for 1.50 or 1.60 – just $20 more to get four more months time for things to swing your way.

👍 109
orinvestor
Irregular
February 2, 2021 1:13 pm
Reply to  cabaoke

Tastytrade (which I use) has lots of free training on options…

https://tastytrade.thinkific.com/

Finguru
Guest
January 27, 2021 1:19 am
Reply to  ddeids

This should help.

https://startoptions.com/call-options/

Options are more volatile so make sure you read and understand fully.

Add a Topic
Options
Add a Topic
Call options
orinvestor
Irregular
January 26, 2021 6:58 pm
Reply to  hedy1234

Was as low as about $7.6 on 01/26 so I put in an alert at $7.99 today. If it drops below that I’ll get an email and will consider an ITM Jan22 call option and selling a Feb 19 Call against it. And possible a put spread to reduce my breakeven point even further.

jazzman777
Member
jazzman777
January 26, 2021 6:19 pm

How come everything is touted after it has gone up 30 to 50%^

👍 21718
Jim
Guest
Jim
January 27, 2021 7:06 pm

Great article. Extremely informative. Thank you. I bought those same Jan ‘22s calls this morning. In addition to having tremendous potential to commercialize life saving cancer drugs, the leader of the Reddit mob has pointed to CLVS as one of the 3 most heavily shorted stocks under $10 along with AMC and KOFF. Well, we’ve seen what’s happened with both of those, they’re up 400-500% in a day. These short squeeze are epic and I’m not understanding why it hasn’t happened with CLVS as well. Maybe it’s about to happen. If it provides the company with a ton of cash that can only help them in their pursuit of getting these drugs into the hands of doctors all over.

Add a Topic
3397
Add a Topic
4529
timcoahran
Irregular
January 28, 2021 1:01 am
Reply to  Jim

The short traders might start being a little more careful next week!

👍 461
cbaylis
cbaylis
January 26, 2021 6:22 pm

i subscribed to this newsletter and CLVS is the stock being pitched. Travis is correct.

Add a Topic
4529
👍 19
BeSmart
January 26, 2021 6:34 pm

It’s definitely CLVS I purchased a few hundred shares in the $4 range. I have a pharmaceutical background. It sounds promising.

Add a Topic
4529
👍 91
Sue
Member
Sue
January 26, 2021 8:14 pm
Reply to  BeSmart

It’s at 8.45 now.. is it a good buy at this price?

Lewis B
Lewis B
May 8, 2022 12:17 am
Reply to  BeSmart

Hi BeSmart,

Will Rubraca be the best first-line drug to treat HRD (-) ovarian cancer?
Can CLVS still make it to $5?

👍 27
easymoney
Guest
easymoney
January 26, 2021 6:52 pm

WOW! For the first time I have a large position at half the current price in a stock someone is hyping. I bought because friend from large medical research facility said CLVS had a lot of promise and would not be surprised if BMY bought them out. He did not say it was sure thing. He knew I was looking for speculation with a lot of potential upside. Did not have a clue on who you were going to name until you actually said it was CLVS. So far things are going great with the items they are in tests in now according to my source. Fingers crossed and love the recent action. A portion of the move will come from huge short position in the stock that has hardly been covered yet. Several stocks with big shorts outstanding have been running big time. A lot of that action seems to be coming from that Reddit site.

Blackie
Blackie
January 26, 2021 10:47 pm
Reply to  easymoney

If I was in CLVS at $4.10 or less and the stock is at $8.21, I’d sell enough shares to “get back” my original investment and then let to rest ride, i.e., play with house money. Actually I am in it at $6.35.

Add a Topic
4529
👍 108
easymoney
Guest
easymoney
January 27, 2021 2:01 pm
Reply to  Blackie

I will hold for the teens or higher. Been in and out of this stock 3 other times. Each time made nice profit. Probably have zero cost basis now but this run is different than the others. I believe there will be good news coming on testing, of shorts have not started to cover yet there is another boost and with the stuff they have in their pipeline they could be good acquisition. Good luck with your position.

johanvanden
johanvanden
January 26, 2021 7:20 pm

Lynparza made by Astrazeneca is the newer parp inhibitor.

👍 2
dmkoch65
January 26, 2021 8:19 pm

This stock has run up into the 90’s -twice both in 2015 and 2017!!! I hoping this third time in 2021 will be a charm! Thanks Travis for sharing this with the group. I’ll see about getting in tomorrow.

👍 6
👍 21718
Piano Jeff
Member
Piano Jeff
January 26, 2021 10:11 pm

Travis…I’m always a bit wary of any $8/share stock that has a negative $5 earnings per share. To my (perhaps layman?) mind, that suggests to me a company that’s not very financially solvent. Is this a valid conclusion or am I being totally off base in that observation?

👍 21718
frndawg
frndawg
January 26, 2021 11:22 pm

Sounds very promising.
Almost like an Immunotherapy Cancer Stock called CEL-SCI Ticker CVM $14.49
Completed Phase III awaiting FDA Review.
Travis, I would appreciate your input on this stock. Appears to be similar in that they are also looking to be used as a First Line Therapy.

Add a Topic
5187
Add a Topic
3397
Add a Topic
4528
👍 4
Newaluxer
Newaluxer
January 28, 2021 3:53 am
Reply to  frndawg

CVM went up $10 to $25 today.

Add a Topic
CVM
ptrcklski
ptrcklski
January 26, 2021 11:56 pm

Pardon my confusion, but when I put together the values quoted in this hype, 1000% doesn’t seem to fit into the equation where $5000 invested turns into $50,000.

Add a Topic
4529
Add a Topic
12219
👍 1
timcoahran
Irregular
January 27, 2021 12:24 am

Slightly off subject, but since Dylan Jovine said that his double-year newsletter guaranty only applies to customers who invest $10k in risky microcaps — I bet he doesn’t have to worry about getting too many claims!

Add a Topic
160
👍 461
Michael
Member
Michael
January 27, 2021 3:47 am

I just wanted to add that this is one of the 1-5 stocks currently on the short squeeze list from the wallstreet bet community on Reddit. So it could be the next $GME in the short-term but investors should know that it could be a wild ride with lot of volatility. So just be careful with this one.

Add a Topic
Wallstreetbet
meridian
meridian
January 27, 2021 9:45 am

Good to know that Gumshoe believes in it enough to buy options. The technicals are good, I just entered a long trade with target $18.60.

Add a Topic
570
👍 40
Calvin K. Grier Sr
Member
Calvin K. Grier Sr
January 27, 2021 10:53 am

how do I get in?

ytse
ytse
January 27, 2021 2:05 pm

Dear Travis,
Couple months back of 2020, I read an article here about RYTM, I bought 1000 shares about $17.00 before PDUFA. Today Stifel says its shares are “CHEAP”, they boost price target by 86%, from $36 to $67. I just bought 1000 shares
of CLVS, now I just wait………

👍 175
👍 21718
iltrus
Irregular
January 28, 2021 1:07 am

Hello Travis, I too stay away from biotech, as I do not know much about the field and I am a rookie in investing. But I did buy a tiny position in Oramed ( ORMP) that has the first oral (capsule) insulin for diabetics in stage 3 trials. They also have stage 2 oral drug for NASH (fatty liver). Diabetics market being so big, I put my toe in the water. I would love to hear your thoughts on Oramed too, if at all possible. Thanks and good luck to all 🙂

Add a Topic
5978
Add a Topic
540
👍 240
👍 21718
iltrus
Irregular
January 28, 2021 10:21 am

Thank you Travis, for being there <3

👍 240
jbmaverick
February 1, 2021 4:22 pm
Reply to  ytse

Here’s some encouragement, ytse – just before the Covid-19 crash about this time last year, CLVS was trading at $11 per share…and had been at nearly $15 a share in late 2019. If you look WAY back, it’s historically found support at the $12 to $15 level several times. While it’s not great that we’re below that level now, a break back above it would look promising.
Personally, I’m fine with it taking out it’s all time high just under $100 a share. If it doubled from THERE, you might realize a nice profit. 🙂

Add a Topic
4529
👍 109
ytse
ytse
January 27, 2021 2:15 pm

BTW, I like RYTM very much because in America every where I look, there are too many fat, yes fat people . Even Uncle Sam has problem of recruiting young people because they are too FAT! The market for Off-label use of Imcivree just too big.

Add a Topic
11526
Add a Topic
1508
👍 175
rlevine99
January 27, 2021 4:41 pm
Reply to  ytse

You are right to identify the fat people issue, but are they really the ones that are going to buy this? I’ve never seen a fat person weigh themself at the supermarket. Only fit people

👍 74
Lewis B
Guest
Lewis B
January 28, 2021 1:46 am

Hi Travis,
Thank you for the article as always!
I noticed that you mentioned some additional “short squeeze” trading like we’ve seen in so many stocks recently”, have you counted W, NOK, OSTK and GME?
Thank you again!

Add a Topic
2494
Add a Topic
6162
ISMAIL
Member
ISMAIL
January 28, 2021 3:51 am

what do you think about RESN?

Add a Topic
5028
Anthony
January 31, 2021 3:07 pm

You invite suggestions for potential ten baggers. My favourite is Victory Square Technologies, VSQTF, – it is making a profit of about 12 cents a share, is trading for only 58 cents, is below book value and growing at about 50%. It has a great portfolio of venture companies that it is grooming for public listing and realization of value. Once news about this company spreads, it will become a $25 to $30 stock, ie 60 times future earnings of 50 cents a share in under 5 years time.

Vik
Vik
February 2, 2021 3:01 pm
Reply to  Anthony

Whats your basis for such a price increase. Care to elaborate?

jbmaverick
February 1, 2021 1:32 pm

TRAVIS – Thanks! I followed after you this morning on picking up some January 2022 calls on CLVS – and I’m already up nearly 50%. So, if that trend continues…hmm, let’s see…a 50% return on investment every trading day…for approximately 200 trading days…(now, you don’t expect it to ever go DOWN in price, do you?)…well, by Christmas this year, that should be about…a gajillion dollars. 🙂

Add a Topic
4529
👍 109
👍 21718

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

More Info  
34
0
Would love your thoughts, please comment.x
()
x